GlassScriptPhysician profile
Andrew T Patterson
NPI 1578954731
$2,102.30
in general payments reported to CMS, 2019-2025
22 companies · $749 in 2025
The $749 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2021: $16.15 · 2022: $438 · 2023: $375 · 2024: $398 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.83 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $374.30 | 2021-2025 | Xarelto, Spravato |
| Teladoc Health, INC. | $300.00 | 2022 | |
| Lilly USA, LLC | $220.27 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $158.87 | 2023-2025 | |
| Janssen Biotech, INC. | $150.65 | 2025 | Tremfya |
| Genentech USA, INC. | $125.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $116.06 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $77.40 | 2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $74.87 | 2023-2024 | Sotyktu |
| Bayer Healthcare Pharmaceuticals INC. | $69.42 | 2024-2025 | |
| Pfizer INC. | $68.16 | 2025 | |
| Organon LLC | $59.73 | 2025 | |
| Leo Pharma INC. | $54.45 | 2024-2025 | Adbry |
| Novo Nordisk INC | $50.69 | 2023-2025 | Wegovy |
| Abbvie INC. | $49.28 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.96 | 2024-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $33.20 | 2023-2024 | Gemtesa |
| Lexicon Pharmaceuticals, INC. | $19.40 | 2023 | Inpefa |
| Incyte Corporation | $18.02 | 2024 | Opzelura |
| Dermavant Sciences, INC. | $16.29 | 2023 | Vtama |
| Convatec INC. | $15.45 | 2025 | |
| Glaxosmithkline, LLC. | $12.83 | 2023 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.